Factors associated with treatment delay in women with primary breast cancer who were referred to reproductive specialists.

Atsuko Kitano
St Luke’s International University

Author Note

Atsuko Kitano, St Luke’s International University Graduate School of Public Health
Correspondence concerning this article should be addressed to Atsuko Kitano
Contact: atsukita@luke.ac.jp
Abstract

Treatment-related infertility is known as a survivorship issues among young breast cancer patients.

Cancer treatment-delay due to fertility preservation procedure can be a barrier for patients who might seek fertility preservation. This study sought to describe any association between fertility preservation and treatment-delay then to assess factors related to treatment-delay. Women diagnosed with breast cancer stages I to III between 2007 and 2015 who visited reproductive unit at our institution were included. Cut-off of treatment-delay was defined as below; time to treatment (TTC) >8 weeks for patients intending to receiving to neoadjuvant chemotherapy, TTC>12 weeks for patients intending to receiving to adjuvant chemotherapy patients, time to endocrine therapy (TTE) >12 weeks for patients intending to receiving endocrine therapy without radiation therapy, and TTE >20 weeks for patients intending to receiving endocrine therapy after radiation therapy.

Multivariable models were constructed to examine factors associated with treatment-delay.

Two-hundred twenty-two patients met the inclusion criteria. Mean TTC among patients who received neoadjuvant chemotherapy or adjuvant chemotherapy was 30.7 days (SD = 29.3) and 65.6 days (SD = 29.5) respectively. Mean TTE without radiation therapy or with radiation was 74.0 days (SD = 51.7) and 124.0 days (SD = 67.5) respectively. Among patients receiving adjuvant chemotherapy, TTC of fertility preservation group was longer than no fertility preservation group (66.3 vs 64.9 days, \( p = 0.03 \)); the treatment-delay rate was not statistically different between the two
Factors associated with treatment delay

groups. Treatment-delay occurred in 18% of patients. Endocrine therapy was a related factor to
treatment-delay (OR, 4.45; 95%CI: [1.01-19.57]; \( p = 0.048 \)), but fertility preservation was not (OR,
1.82 95%CI: [0.88-3.76], \( p = 0.10 \)). Early referral to reproductive specialist is required especially for
patients intending to receive endocrine therapy.

*Key words: breast cancer, fertility, fertility preservation, treatment-delay*